- Home
- MCRB vs DHF Comparison
MCRB vs DHF Comparison
Compare MCRB & DHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- DHF
- Stock Information
- Founded
- MCRB 2010
- DHF 1998
- Country
- MCRB United States
- DHF United States
- Employees
- MCRB N/A
- DHF N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- DHF Finance Companies
- Sector
- MCRB Health Care
- DHF Finance
- Exchange
- MCRB Nasdaq
- DHF Nasdaq
- Market Cap
- MCRB 165.3M
- DHF 189.1M
- IPO Year
- MCRB 2015
- DHF N/A
- Fundamental
- Price
- MCRB $17.23
- DHF $2.62
- Analyst Decision
- MCRB Hold
- DHF
- Analyst Count
- MCRB 4
- DHF 0
- Target Price
- MCRB $73.67
- DHF N/A
- AVG Volume (30 Days)
- MCRB 245.5K
- DHF 451.1K
- Earning Date
- MCRB 11-12-2025
- DHF 01-01-0001
- Dividend Yield
- MCRB N/A
- DHF 7.65%
- EPS Growth
- MCRB N/A
- DHF N/A
- EPS
- MCRB 10.22
- DHF N/A
- Revenue
- MCRB N/A
- DHF N/A
- Revenue This Year
- MCRB N/A
- DHF N/A
- Revenue Next Year
- MCRB N/A
- DHF N/A
- P/E Ratio
- MCRB $1.68
- DHF N/A
- Revenue Growth
- MCRB N/A
- DHF N/A
- 52 Week Low
- MCRB $6.53
- DHF $2.06
- 52 Week High
- MCRB $24.67
- DHF $2.39
- Technical
- Relative Strength Index (RSI)
- MCRB 52.55
- DHF 59.58
- Support Level
- MCRB $17.00
- DHF $2.57
- Resistance Level
- MCRB $24.67
- DHF $2.63
- Average True Range (ATR)
- MCRB 1.79
- DHF 0.02
- MACD
- MCRB -1.40
- DHF 0.00
- Stochastic Oscillator
- MCRB 69.86
- DHF 83.33
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. The fund invests predominantly in fixed-income securities of below-investment-grade credit quality.